ClinicalTrials.gg
CompletedNCT06406348Updated Jul 17, 2025

A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants

A Phase 1 interventional study of ALIA-1758 and Placebo in Alzheimer Disease, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Alzheimer Disease by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · AbbVie.

Enrollment
17th of 27
53 · median 210
Started
2024
the only one that year
Phase 1
7 of 27
none open now
Registered
26th of 27
by date

Among the 27 studies in Alzheimer Disease by AbbVie, this one is the 17th largest by enrollment, is the only one that started in 2024, is one of 7 in phase 1, and was the 26th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 27 studies in Alzheimer Disease by AbbVie is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Alzheimer Disease by AbbVie, or all of them as a file.
02

Study summary

This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of intravenously (IV) or subcutaneously (SC) injected ALIA-1758 in healthy male and female participants.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Participants must understand the nature of the trial and must provide signed and dated written in accordance with local regulations before the conduct of any trial-related procedures.
  • Healthy as determined by the Investigator, based on a medical evaluation including medical history, physical examination, laboratory tests and (ECG) recording. A participant with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if, in the opinion of the Investigator, the finding is (a) unlikely to introduce additional risk to the participant, (b) will not interfere with trial procedures or confound trial results, and (c) is not otherwise exclusionary (see Exclusion Criteria).
  • Body weight of at least 50.0 kg for men and 45.0 kg for women and (BMI) within the range of 17.5-32.0 kg/m2 (inclusive) at Screening.

Key Exclusion Criteria:

  • A history or presence of a hepatic, biliary, renal, gastrointestinal, cardiovascular, endocrine, pulmonary, ophthalmologic, immunologic, hematologic, dermatologic, psychiatric, neurologic abnormality, or chronic urinary tract infections.
  • A clinically significant abnormality on physical examination, ECG, or laboratory evaluations at Screening or between Screening and (first) dose administration.
  • The participant is, in the opinion of the Investigator or Medical Monitor, unlikely to comply with the protocol or is unsuitable for any reason.

Other criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Active

    Single Ascending Dose (SAD) cohorts

    Drug: ALIA-1758

  • Placebo comparator
    Placebo

    Single Ascending Dose (SAD) cohorts

    Other: Placebo

Interventions

  • DrugALIA-1758

    Intravenous or subcutaneous doses

  • OtherPlacebo

    Intravenous or subcutaneous doses

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Incidence, severity, seriousness, and causality of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 85 days after dosing

Secondary outcomes

  1. Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Cmax

    Cmax

    Time frame: 0-85 days after dosing

  2. Pharmacokinetic parameters of ALIA-1758 in healthy subjects: T1/2

    elimination half-life (T1/2)

    Time frame: 0-85 days after dosing

  3. Pharmacokinetic parameters of ALIA-1758 in healthy subjects: AUC

    Area Under Curve (AUC)

    Time frame: 0-85 days after dosing

  4. Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Bioavailability

    Bioavailability after SC administration (F)

    Time frame: 0-85 days after dosing

  5. Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Clearance

    Clearance (CL)

    Time frame: 0-85 days after dosing

  6. Pharmacokinetic parameters of ALIA-1758 in healthy subjects: Volume of distribution

    Volume of distribution (Vz)

    Time frame: 0-85 days after dosing

07

Study locations

1 site
  • Worldwide Clinical Trials Early Phase Services, LLC
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Apr 2025, 11 months.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 11 months is close to that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2024
First posted
May 9, 2024
StartActual
May 9, 2024
Primary completionActual
Apr 22, 2025
CompletionActual
Apr 22, 2025
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06406348
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 9, 2024
Start date
May 9, 2024
Primary completion
Apr 22, 2025
Completion
Apr 22, 2025
Last update
Jul 17, 2025

Study contacts

J. Michael Ryan, M.D.
study director · AbbVie

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion